Page 66 - Read Online
P. 66

Wu et al. Hepatoma Res 2023;9:6  https://dx.doi.org/10.20517/2394-5079.2022.37  Page 13 of 15

               22.      Li S, Lyu N, Han X, et al. Hepatic artery infusion chemotherapy using fluorouracil, leucovorin, and oxaliplatin versus transarterial
                   chemoembolization as initial treatment for locally advanced hepatocellular carcinoma: a propensity score-matching analysis. J Vasc
                   Interv Radiol 2021;32:1267-1276.e1.  DOI  PubMed
               23.      Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular
                   carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J Clin Oncol 2022;40:468-80.  DOI  PubMed
               24.      Bteich F, Di Bisceglie AM. Current and future systemic therapies for hepatocellular carcinoma. Gastroenterol Hepatol (NY)
                   2019;15:266-72.  PubMed  PMC
               25.      Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular
                   carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.  DOI  PubMed
               26.      Bruix J, Qin S, Merle P, et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on
                   sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.  DOI
                   PubMed
               27.      Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose
                   regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol
                   2020;12:1758835920936932.  DOI  PubMed  PMC
               28.      Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J
                   Med 2018;379:54-63.  DOI  PubMed  PMC
               29.      Zhu AX, Kang YK, Yen CJ, et al; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced
                   hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled,
                   phase 3 trial. Lancet Oncol 2019;20:282-96.  DOI  PubMed
               30.      Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin
                   Oncol 2020;38:4317-45.  DOI  PubMed
               31.      Gao X, Huang H, Wang Y, et al. Tumor immune microenvironment characterization in hepatocellular carcinoma identifies four
                   prognostic and immunotherapeutically relevant subclasses. Front Oncol 2020;10:610513.  DOI  PubMed  PMC
               32.      Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised,
                   multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23:77-90.  DOI  PubMed
               33.      Rizzo A, Ricci AD, Di Federico A, et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular
                   carcinoma: Where do we stand? Front Oncol 2021;11:803133.  DOI  PubMed  PMC
               34.      Fukuda H, Numata K, Moriya S, et al. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency
                   ablation-propensity score matching analysis. Radiology 2014;272:598-604.  DOI  PubMed
               35.      Feng X, Xu R, Du X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular
                   carcinoma: a multicenter retrospective cohort study. Am J Gastroenterol 2014;109:1891-9.  DOI  PubMed
               36.      Kan X, Jing Y, Wan QY, Pan JC, Han M, Yang Y, Zhu M, Wang Q, Liu KH. Sorafenib combined with percutaneous radiofrequency
                   ablation for the treatment of medium-sized hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2015;19:247-55.  PubMed
               37.      Bruix J, Takayama T, Mazzaferro V, et al; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or
                   ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-54.  DOI  PubMed
                   PMC
               38.      Jin M, Yu Q, Liu Y, Xu W, Fu X, Ji B. Safety and efficacy of physical thermal ablation combined sorafenib for hepatocellular
                   carcinoma: a meta-analysis. J Clin Transl Hepatol 2021;9:149-159.  DOI  PubMed  PMC
               39.      Wang F, Numata K, Komiyama S, et al. Combination therapy with lenvatinib and radiofrequency ablation for patients with
                   intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh class a liver function: a pilot study. Front
                   Oncol 2022;12:843680.  DOI  PubMed  PMC
               40.      Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-
                   free survival for patients with hepatocellular carcinoma. Int J Cancer 2014;134:342-51.  DOI  PubMed
               41.      Bian H, Zheng JS, Nan G, et al. Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous
                   radiofrequency ablation. J Natl Cancer Inst 2014;106:dju239.  DOI  PubMed
               42.      Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
                   Gastroenterology 2015;148:1383-91.e6.  DOI  PubMed
               43.      Lee JH, Lee JH, Lim YS, et al. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular
                   carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother 2019;68:23-32.  DOI  PubMed  PMC
               44.      Wang X, Liu G, Chen S, et al. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular
                   carcinoma: a propensity score matching analysis. Int J Hyperthermia 2021;38:1519-28.  DOI  PubMed
               45.      Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in
                   advanced hepatocellular carcinoma. J Hepatol 2019;71:1164-74.  DOI  PubMed
                                                                                                    90
               46.      Kaseb AO, Kappadath SC, Lee SS, et al. A Prospective phase II study of safety and efficacy of sorafenib followed by  Y glass
                   microspheres for patients with advanced or metastatic hepatocellular carcinoma. J Hepatocell Carcinoma 2021;8:1129-45.  DOI
                   PubMed  PMC
               47.      Zhan C, Ruohoniemi D, Shanbhogue KP, et al. Safety of combined Yttrium-90 radioembolization and immune checkpoint inhibitor
                   immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol 2020;31:25-34.  DOI  PubMed
   61   62   63   64   65   66   67   68   69   70   71